# Pizarra — PT-pseudo_152344add0f1 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_152344add0f1
Task: 1

Encounter: Urology - outpatient on 06 Jan 2025.
Referrer: Dr. L. Smits (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 70-year-old male
  - PSA: 11.4 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.209 ng/mL²
  - PSA velocity: 2.78 ng/mL/yr
  - Prior PSA: 10.4 ng/mL
  - Prostate volume: 54.66 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.44734785 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 11.4 ng/mL. PI-RADS 5. PSAD 0.21. Prostate volume 55 mL. csPCa 0.45.

Vitals: weight 84 kg, height 178 cm, BMI 26.5, BP 141/79 mmHg, HR 65 bpm. Smoking: Ex-smoker (33 pack-yr, quit 2017).

Chief complaint: Evaluation triggered by a PSA increase to 11.4 ng/mL, which prompted multiparametric MRI.

History: At seventy years of age, this married gentleman shares a home with his partner and previously earned his living as a delivery driver. His initial workup for an elevated PSA began around mid-2023, with serial measurements now tracking upward to 11.4 ng/mL. Urinary function remains largely unaffected; he reports an IPSS score of 2, free from nocturia or a diminished stream. Lifestyle habits include weekend hiking excursions and a modest alcohol intake capped at four units each week. A history of smoking totals 33 pack-years, though he successfully quit in 2017. Mechanical lower back pain currently keeps him in physiotherapy, where six sessions have yielded little relief. Gradual hearing loss over the last ten years means he depends on unambiguous verbal explanations and written notes during visits. He firmly denies any unexplained weight reduction, drenching night sweats, or skeletal discomfort.

Physical examination: DRE — texture: smooth and symmetrically enlarged; mobility: unrestricted; asymmetry: absent. General survey reveals clear pulmonary fields, a regular cardiac rhythm, and a soft, non-tender abdomen. Cognitive status is fully intact, and functional mobility aligns well with his active weekend hiking schedule.

Patient info: delivery driver; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 4 units / week; exercise Hiking on weekends; IPSS score: 2/35 (mild LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.87 +/- 0.11   (95% CI 0.58-1.00)

Where the uncertainty comes from:
  - aleatoric  dA = 0.10  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.04  (few labelled cases resemble this one)
  - 7.4 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'firm': A +/- 1.96*dA does not cross the 0.5 threshold. On the 91 labelled cases this tier was never wrong, but it only covered 17 of them, so the 95% CI on that accuracy still reaches down to ~0.75. Treat it as a strong prior that should only be overturned by explicit contradicting evidence.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=0.0, psa=11.4, age=70.0, psad=0.209, dre_ord=0.0, vol=54.66, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only used the visible panel data (PI-RADS=5, PSA=11.4, Age=70, PSA Density=0.209, DRE=Normal, Volume=54.66 mL) and could not account for the PSA velocity (2.78 ng/mL/yr), the prior PSA (10.4 ng/mL), or the specific context of the guideline criteria (e.g., the specific PSA density cut-offs mentioned in the literature).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy based on a high PI-RADS score (5.0), but the guideline criterion is conditional on PSA density and family history, which the prior did not weigh. The prior's high probability (0.87) could be wrong because the guideline suggests omitting biopsy if PSA density is low (< 0.10 ng/mL/cc) and there is no family history, which might be the case here, contradicting the statistical suggestion.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI? - if it is unchanged the case for sampling weakens; if new or larger it strengthens
PSA history - to assess the trend and velocity beyond the headline value
laboratory panel - to confirm the PSA density value used in guideline risk stratification
previous GP / urology notes - to check for any documented family history of prostate cancer
laboratory panel - to confirm the PSA density value used in guideline risk stratification

GUIDELINE ANCHOR
The guideline states that biopsy should be considered when the mpMRI shows a PI-RADS 3 or higher lesion, but it also suggests omitting biopsy when MRI is negative (PI-RADS $\le$ 2) and clinical suspicion is low (PSA density $< 0.10 \text{ ng/mL/cc}$ and no family history).

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_152344add0f1", "radiology_report": "Subject: Prostate Multiparametric MRI | Reporting Radiologist | 20 January 2025\n\nClinical Context: Assessment of rising prostate-specific antigen (11.4 ng/mL) alongside clinical suspicion for malignancy.\n\nFindings: The gland occupies 54.66 mL of space. T2-weighted sequences highlight a discrete hypointense focus at the base-to-mid left peripheral zone, spanning roughly 18 \u00d7 14 \u00d7 12 mm. Diffusion-weighted imaging shows pronounced restriction with a corresponding low apparent diffusion coefficient. Dynamic contrast sequences capture early, focal enhancement compared to adjacent tissue. No extraprostatic extension or seminal vesicle invasion is visible.\n\nImpression: PI-RADS 5 lesion located in the left peripheral zone (base/mid), approximately 18 mm in diameter. Prostate-specific antigen density calculates to 0.209 ng/mL/mL. csPCa predicted probability stands at 0.44734785."}
get_psa_trend
{"case_id": "PT-pseudo_152344add0f1", "psa_trend": [{"date": "Jul 2023", "val": 7.8}, {"date": "Jan 2024", "val": 1.8}, {"date": "Jul 2024", "val": 5.9}, {"date": "Jan 2025", "val": 11.4}]}
get_previous_notes
{"case_id": "PT-pseudo_152344add0f1", "previous_notes": [{"date": "08 Sep 2024", "author": "Dr. L. Smits (GP)", "text": "Recent outpatient review addressed persistently high PSA values, climbing from 10.4 ng/mL last July to 11.4 ng/mL on the latest draw. The gentleman notes slight lower urinary tract symptoms yet explicitly rules out haematuria or skeletal pain. In light of the rising trend and his age, urology clinic assessment alongside multiparametric MRI scheduling was processed."}]}
get_lab_results
{"case_id": "PT-pseudo_152344add0f1", "laboratory_results": [{"name": "PSA", "val": "11.4 ng/mL", "date": "05 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "2.47 ng/mL", "date": "05 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "22%", "date": "05 Dec 2024", "flag": ""}]}
NOT RETRIEVED
The family history of prostate cancer was not retrieved, which is needed to fully assess the guideline criterion.
WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 5 lesion located in the left peripheral zone, approximately 18 mm in diameter.
- PSA trend: Rising from 10.4 ng/mL (July 2024) to 11.4 ng/mL (Jan 2025), with a velocity of 2.78 ng/mL/yr (from initial data).
AGAINST sampling this patient now:
- Lab results: %Free PSA is 22%, which is not explicitly mentioned as a contraindication in the guideline context provided.
- Guideline context: The guideline suggests omitting biopsy if PSA density is low (< 0.10 ng/mL/cc) and no family history is present.
WHERE THIS LEANS
The high PI-RADS score (5) and the rising PSA trend strongly support the statistical prior and the guideline criterion for biopsy. The lack of documented family history is a mitigating factor against immediate deferral based on the guideline's secondary criteria.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the mpMRI demonstrated a PI-RADS 5 lesion, which is the primary driver for sampling according to the guideline criterion. This finding was supported by the rising PSA trend from 10.4 ng/mL to 11.4 ng/mL and the PSA density of 0.209 ng/mL/mL. The statistical prior and the guideline criterion converged on this decision, and no retrieved evidence contradicted the need for biopsy.

Variables that carried weight: age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
